AU2021250303A1 - Substituted 3-phenoxyazetidin-1-yl-pyrazines having GPR52 agonistic activity - Google Patents
Substituted 3-phenoxyazetidin-1-yl-pyrazines having GPR52 agonistic activity Download PDFInfo
- Publication number
- AU2021250303A1 AU2021250303A1 AU2021250303A AU2021250303A AU2021250303A1 AU 2021250303 A1 AU2021250303 A1 AU 2021250303A1 AU 2021250303 A AU2021250303 A AU 2021250303A AU 2021250303 A AU2021250303 A AU 2021250303A AU 2021250303 A1 AU2021250303 A1 AU 2021250303A1
- Authority
- AU
- Australia
- Prior art keywords
- μmol
- mixture
- disorder
- group
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001640P | 2020-03-30 | 2020-03-30 | |
| US63/001,640 | 2020-03-30 | ||
| PCT/EP2021/058099 WO2021198149A1 (en) | 2020-03-30 | 2021-03-29 | Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021250303A1 true AU2021250303A1 (en) | 2022-09-22 |
Family
ID=75362607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021250303A Abandoned AU2021250303A1 (en) | 2020-03-30 | 2021-03-29 | Substituted 3-phenoxyazetidin-1-yl-pyrazines having GPR52 agonistic activity |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11780827B2 (https=) |
| EP (1) | EP4126850B1 (https=) |
| JP (1) | JP7617134B2 (https=) |
| KR (1) | KR20220161454A (https=) |
| CN (1) | CN115697997B (https=) |
| AR (1) | AR121675A1 (https=) |
| AU (1) | AU2021250303A1 (https=) |
| BR (1) | BR112022018996A2 (https=) |
| CA (1) | CA3176265A1 (https=) |
| CO (1) | CO2022014886A2 (https=) |
| CR (1) | CR20220554A (https=) |
| DO (1) | DOP2022000203A (https=) |
| EC (1) | ECSP22080683A (https=) |
| IL (1) | IL296823A (https=) |
| JO (1) | JOP20220235A1 (https=) |
| MX (1) | MX2022012067A (https=) |
| PE (1) | PE20221918A1 (https=) |
| PH (1) | PH12022552553A1 (https=) |
| TW (1) | TW202204343A (https=) |
| WO (1) | WO2021198149A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202206413A (zh) | 2020-04-22 | 2022-02-16 | 美商紐羅克里生物科學有限公司 | Gpr52調節劑及其使用方法 |
| US12115157B2 (en) | 2021-09-14 | 2024-10-15 | Boehringer Ingelheim International Gmbh | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament |
| CN119143731B (zh) * | 2024-09-13 | 2025-08-26 | 中国海洋大学 | 一种吡嗪酰胺类化合物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2055500A (en) * | 1998-12-23 | 2000-07-31 | Eli Lilly And Company | Aromatic amides |
| WO2009107391A1 (ja) | 2008-02-27 | 2009-09-03 | 武田薬品工業株式会社 | ６員芳香環含有化合物 |
| GB0808668D0 (en) * | 2008-05-13 | 2008-06-18 | Univ Aberdeen | Materials and methods relating to a G-protein coupled receptor |
| JPWO2009157196A1 (ja) | 2008-06-25 | 2011-12-08 | 武田薬品工業株式会社 | アミド化合物 |
| WO2011078360A1 (ja) * | 2009-12-24 | 2011-06-30 | 武田薬品工業株式会社 | アミド化合物 |
| EP2530078A1 (en) * | 2010-01-27 | 2012-12-05 | Takeda Pharmaceutical Company Limited | Thiazole derivative |
| WO2011145735A1 (ja) * | 2010-05-21 | 2011-11-24 | 武田薬品工業株式会社 | チアゾール誘導体 |
| WO2012020738A1 (ja) * | 2010-08-09 | 2012-02-16 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2012076063A1 (en) * | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| KR20180004193A (ko) * | 2015-04-29 | 2018-01-10 | 아레나 파마슈티칼스, 인크. | Gpr52와 관련된 장애의 치료 또는 예방을 위한 gpr52 조절제로서 1-헤테로아릴-인돌린-4-카르복스아미드 |
| AU2016324317A1 (en) * | 2015-09-17 | 2018-03-08 | Coda Biotherapeutics, Inc. | Compositions and methods for treating neurological disorders |
-
2021
- 2021-03-29 BR BR112022018996A patent/BR112022018996A2/pt not_active Application Discontinuation
- 2021-03-29 AR ARP210100766A patent/AR121675A1/es not_active Application Discontinuation
- 2021-03-29 KR KR1020227038002A patent/KR20220161454A/ko not_active Withdrawn
- 2021-03-29 CR CR20220554A patent/CR20220554A/es unknown
- 2021-03-29 AU AU2021250303A patent/AU2021250303A1/en not_active Abandoned
- 2021-03-29 EP EP21716133.0A patent/EP4126850B1/en active Active
- 2021-03-29 JP JP2022559709A patent/JP7617134B2/ja active Active
- 2021-03-29 TW TW110111402A patent/TW202204343A/zh unknown
- 2021-03-29 IL IL296823A patent/IL296823A/en unknown
- 2021-03-29 MX MX2022012067A patent/MX2022012067A/es unknown
- 2021-03-29 CN CN202180025462.7A patent/CN115697997B/zh active Active
- 2021-03-29 WO PCT/EP2021/058099 patent/WO2021198149A1/en not_active Ceased
- 2021-03-29 PE PE2022002146A patent/PE20221918A1/es unknown
- 2021-03-29 PH PH1/2022/552553A patent/PH12022552553A1/en unknown
- 2021-03-29 CA CA3176265A patent/CA3176265A1/en active Pending
- 2021-03-29 US US17/215,759 patent/US11780827B2/en active Active
-
2022
- 2022-09-23 DO DO2022000203A patent/DOP2022000203A/es unknown
- 2022-09-28 JO JOJO/P/2022/0235A patent/JOP20220235A1/ar unknown
- 2022-10-18 EC ECSENADI202280683A patent/ECSP22080683A/es unknown
- 2022-10-19 CO CONC2022/0014886A patent/CO2022014886A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3176265A1 (en) | 2021-10-07 |
| EP4126850B1 (en) | 2024-04-17 |
| CN115697997A (zh) | 2023-02-03 |
| PH12022552553A1 (en) | 2024-01-03 |
| MX2022012067A (es) | 2022-10-13 |
| DOP2022000203A (es) | 2022-11-30 |
| IL296823A (en) | 2022-11-01 |
| US20220356172A1 (en) | 2022-11-10 |
| JP7617134B2 (ja) | 2025-01-17 |
| CR20220554A (es) | 2023-01-09 |
| KR20220161454A (ko) | 2022-12-06 |
| WO2021198149A1 (en) | 2021-10-07 |
| JOP20220235A1 (ar) | 2022-09-28 |
| US11780827B2 (en) | 2023-10-10 |
| EP4126850A1 (en) | 2023-02-08 |
| BR112022018996A2 (pt) | 2022-11-01 |
| CO2022014886A2 (es) | 2022-10-31 |
| ECSP22080683A (es) | 2022-11-30 |
| AR121675A1 (es) | 2022-06-29 |
| CN115697997B (zh) | 2024-07-30 |
| TW202204343A (zh) | 2022-02-01 |
| PE20221918A1 (es) | 2022-12-29 |
| JP2023522307A (ja) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114163444B (zh) | 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用 | |
| EP4126850B1 (en) | Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity | |
| JP2010523530A (ja) | タンパク質キナーゼ阻害剤として有益な［２，６］ナフチリジン | |
| JP2011168617A (ja) | 神経変性疾患の治療において有用なアナバセイン誘導体 | |
| KR101567116B1 (ko) | Ｎｋ1 수용체 길항제로서의 5-[5-[2-(3,5-비스(트리플루오로메틸)페닐)-2-메틸프로파노일메틸아미노]-4-(4-플루오로-2-메틸페닐)]-2-피리디닐-2-알킬-프롤린아미드 | |
| EP4402138B1 (en) | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament | |
| KR20240013134A (ko) | 시그마 리간드로서 피리딘-술폰아미드 유도체 | |
| NO309190B1 (no) | Neurobeskyttende kromanforbindelser og farmasöytisk blanding | |
| EP3810593A1 (en) | Oga inhibitor compounds | |
| EP2266976B1 (en) | Fused ring thrombin receptor antagonists | |
| JPWO2014192868A1 (ja) | 環状アミノメチルピリミジン誘導体 | |
| WO2007007072A1 (en) | 5-htx modulators | |
| KR102728343B1 (ko) | 이미다조피리딘 유도체 및 이의 약제로서의 용도 | |
| WO2024091541A1 (en) | Compounds and compositions as gpr52 modulators | |
| JP2017524736A (ja) | アルファ７−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物 | |
| KR20200123416A (ko) | 이중 5-ht2a 및 5-ht6 수용체 대항제들로서의 인돌 및 벤즈이미다졸 유도체들 | |
| JP2020505459A (ja) | 化合物 | |
| KR20240017785A (ko) | 시그마 리간드로서 신규 (호모)피페리디닐 헤테로사이클 | |
| PL245933B1 (pl) | (Chinolino lub izochinolino) sulfonamidy amin cyklicznych, kompozycja je zawierająca, sposób ich wytwarzania oraz ich zastosowanie medyczne | |
| US20190062305A1 (en) | Pyridyl or pyrazinyl compounds carrying a methyl-bound alpha-amino acid amide group | |
| EP2958912A1 (en) | Pyridine derivatives as 5-ht6 receptor antagonists | |
| JP2021504357A (ja) | ムスカリン性ｍ１受容体ポジティブアロステリックモジュレーターとしての置換アザ環 | |
| WO2006115134A1 (ja) | 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |